OPEN END TURBO LONG - ZEALAND PHARMA | Real-time Bid/Ask 06:59:40 23/05/2024 pm IST | ||
| 0.93 EUR / 0.98 EUR | +13.69% |
|
| Current month | -24.32% | ||
| 1 month | +147.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
| Date | Price | Change |
|---|---|---|
| 23/24/23 | 0.97 | +15.48% |
| 22/24/22 | 0.84 | +15.07% |
| 21/24/21 | 0.73 | -1.35% |
| 20/24/20 | 0.74 | -5.13% |
| 17/24/17 | 0.78 | -3.70% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 06:18 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG1YMK |
| ISIN | DE000MG1YMK9 |
| Date issued | 09/04/2024 |
| Strike | 556 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.64 € |
|---|---|
| Lowest since issue | 0.34 € |
| Spread | 0.05 € |
| Spread % | 5.10% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
613.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+28.05%
- Stock Market
- Certificates
- Certificat
